BioTuesdays

Tag - Andy Hsieh

Cardiff Oncology

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

Icosavax

WB starts Icosavax at outperform

William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...

Vaccitech

WB starts Vaccitech at OP

William Blair initiated coverage of Vaccitech plc (NASDAQ:VACC) with an “outperform” rating. The stock was quoted at $14.35 in afternoon trading on May 25. Vaccitech is a clinical-stage biotechnology company that...

WB starts Aravive at OP

William Blair launched coverage of Aravive (NASDAQ:ARAV) with an “outperform” rating, saying that an “appreciable market disconnect exists between lead asset AVB-500’s potential to emerge as a differentiated therapeutic...

BeyondSpring Logo

WB starts BeyondSpring at outperform

William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.